On March 26, INSYS Therapeutics, Inc., a Phoenix-based specialty pharmaceutical company, and drug delivery firm Aptar Pharma, announced the U.S. launch of INSYS Therapeutics’ SUBSYSTM, which uses an Aptar Pharma sublingual (under the tongue) Unit-Dose Spray (UDS) device for breakthrough cancer pain in patients age 18 and older and who are already tolerant to opioid therapy.
The new dosage form/single unit-dose delivery device disperses a fine mist over a broad sublingual area. The spray is indicated for the treatment of breakthrough cancer pain in opioid-tolerant adult patients who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Breakthrough cancer pain occurs in patients with cancer and is often defined as a temporary flare in pain that can be quite severe. These flares occur in the context of background pain that is otherwise usually controlled with opioids.



















